Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855562 | 0.87 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3HRH1CCR3 | |
| SCHEMBL30734735 | 0.83 | AR (0.39) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL26635517 | 0.83 | AR (0.39) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL26635519 | 0.83 | AR (0.39) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL24088392 | 0.80 | L3MBTL1 (0.44) | MRGPRX4ALDH1A1ENPP2 | |
| SCHEMBL21855519 | 0.80 | L3MBTL1 (0.41) | SLC6A4SLC6A2SLC6A3HRH1CCR3 | |
| SCHEMBL30663016 | 0.77 | AR (0.38) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL26635834 | 0.77 | AR (0.38) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL26636543 | 0.77 | AR (0.38) | HRH1CCR3ESR2OPRK1KCNH2 | |
| SCHEMBL30663180 | 0.76 | AR (0.37) | ESR2OPRK1KCNH2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867232-B1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12152019-B2 | Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2020081381-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081381-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152019-B2 | Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, AADAC | SLC6A4 540/4885SLC6A2 1104/4885SLC6A3 639/4885 |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, AADAC | SLC6A4 356/4885SLC6A2 853/4885SLC6A3 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.